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A B S T R A C T
There are several lines of evidence that opioidergic and nitrergic systems could modulate the seizure
threshold. We previously have shown that sildenaﬁl had proconvulsant effects in a model of clonic
seizure induced by pentylenetetrazole (PTZ) or bicuculline. In the present study, we examined whether
the opioid system participates in the action of sildenaﬁl on the PTZ-induced clonic seizures in mice.
Sildenaﬁl (1, 5, 10 and 20 mg/kg, i.p.) signiﬁcantly decreased the seizure threshold in a dose-dependent
manner, whereas morphine had both anticonvulsant and proconvulsant effects at low (0.5, 1, and 3 mg/
kg, s.c.) and high (60 mg/kg, s.c.) doses. A sub-effective dose of sildenaﬁl (5 mg/kg) combined with a dose
of morphine (7.5 mg/kg) which was sub-effective for its proconvulsant effects signiﬁcantly decreased
the seizure threshold. Although naltrexone at 0.5 and 1 mg/kg had no effect on the seizure threshold, it
signiﬁcantly prevented both the proconvulsant effects of sildenaﬁl as well as the anticonvulsant and
proconvulsant effects of morphine on the PTZ-induced seizure thresholds. Our data suggested a role for
opioidergic system in the proconvulsant effects of sildenaﬁl on the PTZ-induced clonic seizures in mice.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Intracellular cyclic guanosine monophosphate (cGMP) concen-
tration is regulated through the control of guanylyl cyclase activity
and the rate of degradation by cGMP-speciﬁc phosphodiesterase
(PDE). Nitric oxide (NO) activates soluble guanylyl cyclase, thereby
catalyzing the production of cGMP from GTP, whereas cGMP-
speciﬁc PDE catalyzes the hydrolysis of cGMP to GMP ending signal
transduction.1 Several PDEs are speciﬁc for cGMP, however, PDE-5
isoenzyme seems to be the most relevant enzyme in cGMP
inactivation in cells.
Sildenaﬁl citrate is a drug which is mainly used for the
treatment of male erectile dysfunction.1 Actions of sildenaﬁl are
widely mediated by NO/cGMP system. As a selective PDE-5
inhibitor, sildenaﬁl increases intracellular cGMP and therefore,
enhances the effect of NO in target tissues.2,3 Several direct effects* Corresponding author. Tel.: +98 21 6611 2802; fax: +98 21 6640 2569.
E-mail addresses: m82_ghasemi@yahoo.com, mghasem2@jhmi.edu
(M. Ghasemi), dehpour@yahoo.com (A.R. Dehpour).
1 Present address: Neuroregeneration and Stem Cell Program, Institute for Cell
Engineering, Departments of Neurology and Neuroscience, Johns Hopkins
University School of Medicine, 733 North Broadway, Baltimore, MD 21205, United
States.
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.01.014of sildenaﬁl administration on the nervous system have been
reported in both humans and rodents, including antinocicep-
tion.4,5 It has also been suggested that sildenaﬁl may have
proconvulsant activity in humans.6 Riazi et al. also reported that
sildenaﬁl decreased the threshold for clonic seizures induced by
intravenous administration of pentylenetetrazole (PTZ) and
bicuculline and they suggested NO/cGMP pathway as a possible
mediator.7
It is well known that opioids have both anticonvulsant and
proconvulsant effects on seizure threshold.8,9 Different studies
reported that low doses ofmorphine show an anticonvulsant effect
against seizures induced by GABA-transmission blockers like
picrotoxin, bicuculline, PTZ, and isoniazid, whereas higher doses of
this opioid-receptor agonist increase the susceptibility of animals
to the same seizure models.8,10 Biphasic effects of morphine on
chemical and electrical models of seizure are inhibited by sensitive
doses of the m-opioid receptor antagonist naloxone.11,12 There is
some evidences that NO pathways play a role in both phases of
morphine-induced modulation of PTZ-induced seizures.13
In previous reports, interaction between opioid system and NO
signaling pathway in modulating PTZ-induced clonic seizures in
mice has been shown.10,14 The aim of the present study is to
evaluate the effect of opioid system on the proconvulsant
consequences of sildenaﬁl in the same model.vier Ltd. All rights reserved.
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Fig. 1. Effect of different doses of morphine (0.25, 0.5, 1, 3, 7.5, 15, 30, and 60 mg/kg,
s.c.) on the PTZ-induced seizure threshold in mice. Morphine was administered
60 min before PTZ. Data are expressed as mean  S.E.M. of at least 8 mice. *P < 0.05
and ***P < 0.001 compared with saline group; ns, non-signiﬁcant.
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Fig. 2. Effect of different doses of sildenaﬁl (1, 5, 10, and 20 mg/kg, i.p.) on the PTZ-
induced seizure threshold in mice. Sildenaﬁl was administered 30 min before PTZ.
Data are expressed as mean  S.E.M. of at least 8 mice. *P < 0.05 and ***P < 0.001
compared with saline group.
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2.1. Animals
Male NMRI mice, weighing 20–30 g from our center breeding
facilities were used in this study. The animals were placed in a
temperature-controlled (22  3 8C) colony room on a 12-h light/12-h
dark cyclewith adequate and free access to food andwater. All animals
were adapted to the laboratory environment at least three days prior to
the initiation of the procedure. 13:00 h with normal room light (12-h
regular light/dark cycle) and temperature (22  1 8C). All procedures
were carried out in accordancewith institutional guidelines for animal
care and use. Each mouse underwent treatment once and each
treatment group consisted of 8–10 animals.
2.2. Drugs
Morphine sulfate, naltrexone and PTZ were purchased from
Sigma (Bristol, UK). Sildenaﬁl citrate was a generous gift from
Poursina Institute (Tehran, Iran). All drugs were dissolved in sterile
physiological saline solution with appropriate concentrations that
were administered in the volume of 5 ml/kg of mice body weight.
PTZ was prepared in physiological saline as 1% solution for
intravenous injections. In all study groups, sildenaﬁl and naltrex-
onewere administered intraperitoneally (i.p.) whilemorphinewas
administered subcutaneously (s.c.).
2.3. Determination of seizure threshold
Threshold of PTZ-induced seizurewas assessedby inserting a 30-
gaugedentalneedle into the tail veinofmiceand infusionofPTZ (1%)
with constant rate of 1 ml/min to unrestrained animals. Infusion
continued until forelimb clonus accompanied by full clonus of the
body. An index of seizure threshold deﬁned as minimal dose of PTZ
(mg/kg of mice weight) needed to induce clonic seizure.15
2.4. Experiments
In experiment 1, animals received different doses of morphine
(0.25, 0.5, 1, 3, 7.5, 15, 30, and 60 mg/kg, s.c.) 60 min before PTZ.
Animals in experiment 2 received different doses of sildenaﬁl (1, 5,
10, and 20 mg/kg, i.p.) 30 min prior to the determination of the PTZ-
induced clonic seizure threshold. In experiment 3, two sub-effective
doses ofmorphine (0.25 and7.5 mg/kg) administered 30 min before
a sub-effective doses of sildenaﬁl (5 mg/kg) and 1 h before PTZ. In
experiment 4, naltrexone (0.5 and 1 mg/kg, i.p.) was administered
15 minbefore sildenaﬁl (10 and20 mg/kg) and45minbefore PTZ. In
experiment 5, naltrexone (0.5 and 1 mg/kg) was administered
15 min beforemorphine (0.5, 1, 3, and 60 mg/kg) and 75 min before
PTZ. In all experiments saline controlwas included. Doses of applied
drugs were chosen based on previous published articles.7,16
2.5. Statistical analysis
Data are expressed as mean  S.E.M. of clonic seizure threshold
in each experimental group. The one-way or two-way analysis of
variance (ANOVA) followed by the Student–Newman–Keuls post hoc
test was used to analyze the data. P < 0.05 was considered as the
signiﬁcance level between the groups.
3. Results
3.1. Effect of different doses of morphine on clonic seizure threshold
Fig. 1 illustrates the biphasic effect of subcutaneous adminis-
tration of different doses of morphine (0.25, 0.5, 1, 3, 7.5, 15, 30,and 60 mg/kg) on PTZ-induced clonic seizure threshold
(F8,65 = 40.131; P < 0.0001). Low doses of morphine (0.5, 1, and
3 mg/kg) were signiﬁcantly anticonvulsant with maximum in-
crease in the seizure threshold at 1 mg/kg (P < 0.001). Morphine at
higher doses of 15 and 30 mg/kg decreased but this was not
signiﬁcant. Statistically signiﬁcant proconvulsant effect was
observed only at 60 mg/kg (P < 0.001).
3.2. Effect of sildenaﬁl on clonic seizure threshold
Fig. 2 shows the effect of different doses of intraperitoneal
injection of sildenaﬁl (1, 5, 10, and 20 mg/kg) on seizure threshold
(F4,42 = 8.146; P < 0.0001). Sildenaﬁl at two doses of 10 and 20 mg/
kg signiﬁcantly decreased the seizure threshold compared to saline
control group.
3.3. Effect of pretreatmentwith sub-effective doses ofmorphine on the
proconvulsant effect of sildenaﬁl
As shown in Fig. 3A and B, morphine at 0.25 mg/kg (a sub-
effective dose for its anticonvulsant effect) accompanied by sub-
effective dose of sildenaﬁl at 5 mg/kg had no signiﬁcant effect on
the seizure threshold (P > 0.05), but concomitant administration of[()TD$FIG]
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Fig. 3. Effect of pretreatment with morphine at 0.25 mg/kg and 7.5 mg/kg on the
effect of sildenaﬁl (5 mg/kg, i.p.) on the PTZ-induced seizure threshold in mice.
Morphine was administered 30 min before sildenaﬁl and 60 min before PTZ. Data
are expressed as mean  S.E.M. of at least 8 mice. **P < 0.01 compared with saline/
saline group; #P < 0.05 comparedwith corresponding morphine/saline group; ns, non-
signiﬁcant.
L. Montaser-Kouhsari et al. / Seizure 20 (2011) 409–413 411morphine at 7.5 mg/kg (whichwas sub-effective for proconvulsant
effect) with same sildenaﬁl dose signiﬁcantly exerted a procon-
vulsant effect (F3,30 = 4.712; P = 0.0082).
3.4. Effect of naltrexone on anticonvulsant and proconvulsant effects
of morphine
Lowdoses of naltrexonewith no signiﬁcant effect on the seizure
threshold per se (0.5 or 1 mg/kg) signiﬁcantly prevented both
anticonvulsant and proconvulsant effects of morphine.
3.5. Effect of naltrexone on proconvulsant effect of sildenaﬁl
The effect of different doses of naltrexone (0.5 and 1 mg/kg) on
the proconvulsant effect of sildenaﬁl is depicted in Fig. 4
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Fig. 4. Effect of pretreatment with naltrexone (NLX) at 0.5 and 1 mg/kg on the
proconvulsant effects of sildenaﬁl (10 and 20 mg/kg, i.p.) on the PTZ-induced
seizure threshold in mice. NLX was administered 15 min before sildenaﬁl and
45 min before PTZ. Data are expressed as mean  S.E.M. of at least 8 mice. **P < 0.01
and ***P < 0.001 compared with saline/saline group; #P < 0.05 and ##P < 0.01
compared with corresponding NLX/saline group.(F8,66 = 5.779; P < 0.0001). Pretreatment with naltrexone at
0.5 mg/kg inhibited the proconvulsant effect of sildenaﬁl and this
effect was signiﬁcant (P < 0.01) at 20 mg/kg of sildenaﬁl
(F4,45 = 8.133; P < 0.0001). Moreover, pretreatment with naltrex-
one at 1 mg/kg signiﬁcantly prevented the proconvulsant effect of
both 10 and 20 mg/kg of sildenaﬁl (F4,45 = 9.89; P < 0.0001).
4. Discussion
By using PTZ-induced clonic seizure threshold, which is a well
documented method for evaluating the modulatory effects of
different drugs in seizure susceptibility,17 we demonstrated that
sub-effective doses of morphine and sildenaﬁl show an additive
effect in decreasing the seizure thresholds. The opioid receptor
antagonist naltrexone abolished the proconvulsant effect of
sildenaﬁl, suggesting a role for opioid system in modulating the
proconvulsant effect of sildenaﬁl on the PTZ-induced clonic seizure
in mice. The biphasic effect of morphine and dose-dependent
proconvulsant effect of sildenaﬁl was conﬁrmed in our ﬁrst two
experiments.
It is well known that opioids (morphine) exert different effects
on seizure threshold based on their dose and the models.8,18 While
low doses of morphine show an anticonvulsant effect against
seizure models induced by GABA-transmission blockers, PTZ,
picrotoxin, bicuculline and isoniazid,8,19 higher doses of this opioid
receptor agonist increase the susceptibility of animals to the same
seizure models.9 Endogenous opioids could protect against
electroconvulsive shock-induced seizures20 and are involved in
the anticonvulsant properties of acute stress21. However, mor-
phine at very high doses induces seizure by itself.22 In the present
study we consistently observed that low doses of morphine (0.5–
3 mg/kg) had anticonvulsant effects on the PTZ-induced seizure
threshold, whereas morphine at 60 mg/kg exerted proconvulsant
effects. We also showed that both anticonvulsant and proconvul-
sant effects of systemic morphine on the seizure thresholds were
m-opioid receptor mediated since they were reversible by the m-
opioid receptor antagonist naltrexone, which is in line with
previous results using several m-opioid receptor antagonists such
as naloxone and naltrexone.8,10,23
Sildenaﬁl is a potent, selective and reversible PDE524 that blocks
cGMP hydrolysis, thereby enhancing the effects of NO in the target
tissues such as corpus cavernosum.25,26 However, the extent and
impact of central effects of sildenaﬁl has not been completely
elucidated. The recent clinical evidence also suggests that
sildenaﬁl may lead to tonic–clonic seizures and inducing relapse
of bipolar disorder.6,27,28 In animal models, there is some evidence
that sildenaﬁl could modulate the antinociceptionmechanistically
distinct models of pain perception such as tail-ﬂick (spinal and
supra-spinal), hot plate (supra-spinal) acetic acid writhing and
formalin (peripheral) tests.4,29–31 Moreover, some studies have
demonstrated that sildenaﬁl exerted an anxiogenic effect in the
elevated plus maze test in mice alone or in combination with the
NOS substrate L-arginine.16,32 Sildenaﬁl was also reported to
prevent the antidepressant-like effects of some drugs including
lithium33 and bupropion34 in animal models of depression in
rodents. Another study showed the proconvulsant effect of
sildenaﬁl to reverse anticonvulsive properties of diazepam in
PTZ-induced clonic seizure model.35 Regarding seizure models
caused by mechanism other than GABAergic manipulations,
sildenaﬁl did not change the latency to cocaine-induced clonic
seizure inmice.36 Conversely, sildenaﬁl increased the threshold for
electroconvulsions in mice in a dose-dependent manner. It also
increased the anticonvulsant activity of carbamazepine, valproic
acid and topiramate in the maximal electroshock seizure test.37
These differences in results may be due to the differences in the
models of seizures used in the previous studies. In the present
L. Montaser-Kouhsari et al. / Seizure 20 (2011) 409–413412study, we showed that sildenaﬁl resulted in a dose-dependent
decrease in the PTZ-induced clonic seizure inmice, which is similar
to our previous studies.7,35 The mechanism of the reported central
effects of sildenaﬁl is not well understood but there is evidence
that NO/cGMP pathway may play a role in the aforementioned
central effects of sildenaﬁl.7,31,32,35 Accordingly, activation of NO
overproduction by high doses of L-arginine has been shown to
decrease PTZ-induced seizure threshold.38
Our data also revealed that when low and per se non-effective
dose of sildenaﬁl (5 mg/kg) was administered together with a
given dose of morphine (7.5 mg/kg), which was sub-effective for
its proconvulsant effects, exerted a signiﬁcant proconvulsant
effects on the PTZ-induced clonic seizure in mice. This result
suggests an interaction between sildenaﬁl and opioidergic
system in decreasing clonic seizure threshold in mice. Accord-
ingly, we further showed that the opioid m-receptor antagonist
naltrexone was able to prevent the proconvulsant effects of
potent doses of sildenaﬁl (10 and 20 mg/kg) on the seizure
threshold, implicating a role foe opioid system in the procon-
vulsant effects of sildenaﬁl. However, despite some evidences
from previous studies in nociception,30 combining sub-effective
sildenaﬁl with low dose morphine (0.25 mg/kg, sub-effective for
its anticonvulsant effect) failed to reach a signiﬁcant difference
from controls (Fig. 3A). This is in contrast with the results from
the results from combining L-arginine with morphine.10 This may
be due to a difference in the mechanism of NO system
modulation between these two agents or simply a difference
not caught by our experiment.
Sildenaﬁl does not act at the level of opiate receptors, therefore
the fact that naltrexone blocked the proconvulsant effects of
sildenaﬁl on the PTZ-induced seizure threshold suggests that
endogenous opioids might have a signiﬁcant participation in the
proconvulsant effects of sildenaﬁl. In fact, there is some evidence
that activation of opioid receptors could modulate NO produc-
tion,39–42 which in turn increases cGMP. As mentioned previously,
this suggestion could be supported by the fact that NO and cGMP
inhibitors are able to reverse either the proconvulsant or
antinociceptive effects of morphine.10,30 When sildenaﬁl is co-
administered with morphine, it signiﬁcantly prevents the cGMP
degradation, leading to accumulation of cGMP and a decrease in
seizure threshold. In agreement with this hypothesis, increased
activity of either excitatory NMDA receptors43 or L-arginine/NO10
subsequent to opioid receptor activation have been proposed as
probable mechanisms that mediate morphine-induced procon-
vulsant and anticonvulsant effects. In addition, the endogenously
released NO participates in the excitatory transmission through
NMDA receptors44 and strong blockade of NO synthesis, by high
doses of NOS inhibitors, has been shown to blocks the PTZ-induced
seizures.7,10 Therefore, it could be suggested that opioid system
plays a role in the proconvulsant effects of sildenaﬁl on the clonic
seizures induced by PTZ inmice. However, this general assumption
awaits additional studies using a variety of seizure models in
rodents or other species. The intravenous timed PTZ infusion
which is used here in particular can be used for measures other
than the generalized clonus threshold, such as observation of ﬁrst
myoclonic jerk and the tonic phase.45
5. Conclusions
In conclusion, the present study demonstrates that the widely
used PDE-5 inhibitor sildenaﬁl interacts with morphine in
affecting mouse seizure susceptibility. The proconvulsant effect
of sildenaﬁl was prevented by the opioid receptor antagonist
naltrexone in the absence of exogenous opioid, indicating a role for
the opioidergic system in the seizure susceptibility effects of NO/
cGMP pathways modulated by sildenaﬁl.References
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